Lurasidone for the treatment of schizophrenia in adult and paediatric populations

• Egile Nagusiak: Teresa Guilera (Egilea), Juan Pablo Chart Pascual (Egilea), Maria del Carmen Blasco (Egilea), Pilar Calvo Estopiñán (Egilea), Rubén Asensio Piernas González (Egilea), Isabel Ramírez Martínez (Egilea), Cristóbal Rodríguez Moyano (Egilea), Rita Prieto Pérez (Egilea), Irene Gabarda-Inat (Egilea), Juan L Prados-Ojeda (Egilea), Marina Diaz-Marsà (Egilea), Manuel Martín-Carrasco (Egilea)
• Formatua: Liburua
• Argitaratua: BioExcel Publishing Ltd, 2023-02-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Schizophrenia is a common debilitating disorder characterized by significant impairments in how reality is perceived, combined with behavioural changes. In this review, we describe the lurasidone development programme for adult and paediatric patients. Both the pharmacokinetic and pharmacodynamic ch...